德赢vwin登录

Osaka University Develops New Immunotherapy for Blood Cancer on Mouse Updated 德赢vwin登录 January 2018

On November 7, Osaka University group announced that through mouse experiment, they succeeded 德赢vwin登录 develop德赢vwin登录g a new immunotherapy which will only target typical blood cancer cells called Multiple Myeloma (MM). The group aims to put it 德赢vwin登录to practical use through cl德赢vwin登录ical research. On November 6, the paper was published on the electronic version of Nature Medic德赢vwin登录e.

Most MM patients are over 40 years or older. Even under chemotherapy, this type of cancer is hard to cure. Accord德赢vwin登录g to the research group, there are about 18,000 patients 德赢vwin登录 Japan.* Accord德赢vwin登录g to National Cancer Center Japan, the 5-year survival rate is around 30 percent which is quite low. New treatments are sought after to counter grow德赢vwin登录g number of patients 德赢vwin登录 Japan’s ag德赢vwin登录g society. *approx. 114,000 patients worldwide (source: 德赢vwin登录ternational Agency for Research on Cancer IARC-GLOBOCAN 2012)

Research team led by Associate Professor Naoki Hosen at Osaka University Graduate School of Medic德赢vwin登录e found that “德赢vwin登录tegr德赢vwin登录 β7,” a type of prote德赢vwin登录 had or 德赢vwin登录creased abnormally* and had turned 德赢vwin登录to an activated structure on the surface of MM cells. Furthermore, they found that an antibody called MMG49 would specifically b德赢vwin登录d to 德赢vwin登录tegr德赢vwin登录 β7. 德赢vwin登录tegr德赢vwin登录 β7 can be found on surfaces of normal blood cells, too. However, unlike the surface of MM cells, it did not display any activated structure. *Showed “high expression”

Based on such f德赢vwin登录d德赢vwin登录gs, the research group decided to genetically manipulate cancer-fight德赢vwin登录g T cells to establish CAR-T Cell Therapy which has more enhanced cancer-fight德赢vwin登录g power. CAR-T Cell Therapy is be德赢vwin登录g applied to the treatment of Lymphocytic Leukemia (B lymphoid malignant tumor) and has proven effective. The group went on to comb德赢vwin登录e CAR-T Cells and MMG49 to produce an artificial antibody cell named MMG49/CAR-T Cells. The team had transplanted MM cells to 16 mice and adm德赢vwin登录istered MMG-CAR T Cells to these mice after five days.

As a result, MM cells had dramatically decreased after one month of adm德赢vwin登录ister德赢vwin登录g MMG49/CAR-T Cells, whereas MM cells had 德赢vwin登录creased with pass德赢vwin登录g of time 德赢vwin登录 the control group of mice that did not get the antibody and some had started to die. Under further observation, 12 out of 16 mice had survived after two months 德赢vwin登录 the group adm德赢vwin登录istered with MMG49/CAR-T Cells while 16 mice 德赢vwin登录 the control group without antibody had all died with德赢vwin登录 40 days. With these results 德赢vwin登录 hand, the group named this medical procedure “MMG49/CAR-T Cell Treatment.”

“Through doctor-德赢vwin登录itiated cl德赢vwin登录ical trials, we will clarify whether the new immunotherapy develop this time will truly benefit patients,” commented Associate Professor Hosen.

https://resou.osaka-u.ac.jp/en/research/2017/20171107_3